TCM
GALT icon

Traynor Capital Management’s Galectin Therapeutics GALT Stock Holding History

Traynor Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-101,600
Closed -$423K – 355
2025
Q4 		$423K Buy
101,600
+2,500
+3% +$13.2K 0.02% 207
2025
Q3 		$420K Buy
99,100
+1,000
+1% +$3.76K 0.02% 203
2025
Q2 		$218K Buy
98,100
+21,180
+28% +$31.7K 0.02% 225
2025
Q1 		$93.8K Buy
76,920
+21,250
+38% +$29.8K 0.01% 228
2024
Q4 		$71.8K Buy
55,670
+12,799
+30% +$30.7K ﹤0.01% 260
2024
Q3 		$118K Hold
42,871
– – 0.01% 246
2024
Q2 		$96.9K Buy
42,871
+8,164
+24% +$24.8K 0.01% 241
2024
Q1 		$83K Hold
34,707
– – 0.01% 245
2023
Q4 		$57.6K Hold
34,707
– – 0.01% 221
2023
Q3 		$66.6K Buy
+34,707
New +$57.1K 0.01% 203

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Traynor Capital Management's GALT Position: Q1 2026 in Review

Traynor Capital Management sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 101,600 shares — an estimated $423K sold.

Traynor Capital Management first reported a position in GALT in Q3 2023 and held it in 10 quarters. The position peaked at $423K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Traynor Capital Management reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Traynor Capital Management sold 101,600 Galectin Therapeutics shares in Q1 2026, an estimated $423K.
  • Traynor Capital Management first reported a position in Galectin Therapeutics in Q3 2023 and held it in 10 quarters.
  • Traynor Capital Management's Galectin Therapeutics position peaked at $423K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Traynor Capital Management's 13F filing for Q1 2026, filed 15 May 2026.